A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 04 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.